BCX-1470 methanesulfonate

Research use only, not for human use.

A serine protease inhibitor that inhibits the esterolytic activity of factor D (IC50=96 nM) and C1s (IC50=1.6 nM).

A serine protease inhibitor that inhibits the esterolytic activity of factor D (IC50=96 nM) and C1s (IC50=1.6 nM); displays 3.4-fold and 200-fold bette than that of trypsin, respectively; inhibits esterolytic activity translates into potent inhibition of the proteolytic activity of C1s, factor D, and consequently of the classical and alternative pathway-mediated hemolysis of target RBC (IC50=46 nM and 330 nM, respectively); blocks the reverse passive Arthus (RPA) reaction in rats. Thrombosis Phase 1 Discontinued.

BCX 1470 methanesulfonate is serine protease inhibitor. BCX 1470 methanesulfonate blocks the esterolytic and hemolytic activities of the complement enzymes Cls and factor D in vitro, also blocked development of RPA-induced edema in the rat.

——

BCX-1470

Immunology/Inflammation

Complement System

Complement System

Cardiovascular Disease

Thrombosis

217099-44-0

398.4771

C15H14N2O5S3

>98% (HPLC)

10 mM in DMSO

CS(=O)(=O)O.C1=CSC(=C1)C(=O)OC2=CC3=C(C=C2)C=C(S3)C(=N)N

2-Thiophenecarboxylic acid, 2-(aminoiminomethyl)benzo[b]thiophen-6-yl ester, methanesulfonate (1:1)

(-20℃)

With Ice Pack

≥ 2 years